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Abstract This study compares the diagnostic performance of
a second generation anti-cyclic citrullinated peptide antibody
(CCP2) with a third generation anti-CCP antibodies assay
(CCP3), as well as the combination of both tests. Serum sam-
ples of 127 patients were analyzed. IgG anti-CCP 2 and IgM
rheumatoid factor were determined by EliA™ technique on a
Phadia 250 instrument (Thermo Fisher Scientific), anti-CCP3
by the Quanta Flash™ anti-CCP3 IgG kit, BIO-FLASHRapid
Response Chemi luminscence Analyzer ( INOVA
Diagnostics). Diagnostic performance was compared using
ROC-curves, sensitivity, specificity, likelihood ratios, and pre-
dictive values. Logistic regressions were used to investigate
whether using both tests (anti-CCP2 and anti-CCP3) gives a
better prediction of rheumatoid arthritis. At the manufacturer’s
cut-offs sensitivity and specificity were 79.4 and 61.0% for
CCP3 and 80.9 and 69.5% for CCP2. No significant differ-
ences could be observed regarding the areas under the curve
(AUC) of both ROC-curves. The optimal cut-off point for
CCP2 was 10.5 U/ml (sensitivity of 75.0% and specificity of
80.0%) and 5.6 U/ml for CCP3 (sensitivity of 86.9% and
specificity of 61.0%). Binary logistic regressions indicated
that the likelihood of having rheumatoid arthritis (RA) is sig-
nificantly higher when testing positive on both CCP2 and
CCP3 compared to CCP2 or CCP3 alone. In our cohort, com-
parable performance was found between the two CCP assays.
Positivity for both CCP2 and CCP3 resulted in the most spe-
cific identification of RA patients. In patients with joint com-
plaints suspected of having RA and with a weakly positive
CCP 2 (≥7 and ≤16 U/ml) CCP3 testing could be of additive
value for diagnosing RA.
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Introduction/objectives
Rheumatoid arthritis (RA) is a heterogeneous condition. This
is well illustrated by the highly variable course the disease
may follow in different individuals. RA is characterized by
inflammation and ultimately damage of the joints. Modern
treatment, therefore, is based on aggressive anti-rheumatic
therapy in the early phase of the disease and consequently
delays the disease progression [1]. Although the diagnosis of
RA is mainly made on clinical grounds, disease-specific
markers are of additional value for an increasing proportion
of the RA patients [2]. Historically, rheumatoid factor (RF)
was the main element in the serological diagnosis of RA and
the only laboratory diagnostic parameter included in the 1987
American College of Rheumatology (ACR) criteria for the
classification of RA [3]. However, RF is not very specific
for this disease and can also be detected in patients with other
rheumatic disorders, infections, as well as in apparently
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healthy individuals [4]. The other tests available at that time
were anti-perinuclear factor and anti-keratin antibody.
However, their diagnostic utilities were initially limited due
to low sensitivity, specificity, and methodology [5].
In 1998, Schellekens et al. [6] introduced an ELISA
based on these original findings now using citrullinated
peptides (CCP). The first generation of anti-CCP antibod-
ies (anti-CCP1) test revealed a higher specificity for RA
in comparison to the RF test [7]. At the end of 2002,
second generation anti-CCP antibodies tests were devel-
oped, with different cyclic peptides and improved perfor-
mance characteristics showing an even better specificity
for RA [7]. Following anti-CCP2, a third generation anti-
CCP test (anti-CCP3) has been developed to increase the
sensitivity for the detection of patients with RA. In sum,
both sensitivity and specificity of the anti-CCP tests are
significantly higher than those of the RF test [8].
Several scholars compared the diagnostic performance
of anti-CCP2 and anti-CCP3, but conflicting evidence
emerges from these studies. On the one hand, several
studies conclude that the anti-CCP3 test has no apparent
diagnostic advantage compared with the anti-CCP2 test
[8–16]. On the other hand, other studies showed a higher
sensitivity of the anti-CCP3 compared to anti-CCP2 tests
[7, 16–18].
Recently, it has been speculated that the reported
higher sensitivity of CCP3 may only be found in co-
horts with early RA, whereas the sensitivity may be
similar in groups with established disease [2, 19]. A
study performed by Jaskowski et al. [20] found no sta-
tistically significant difference in sensitivity and speci-
ficity between anti-CCP3 and anti-CCP2. Instead, they
showed that anti-CCP3 antibodies were more prevalent
than anti-CCP2 antibodies in RF-negative RA patients.
These results were confirmed by a study performed by
Swart et al. [19] comparing two anti-CCP tests using a
routine patient cohort. They found that discrimination
between RA and non-RA patients was better using
CCP3. The most pronounced difference between CCP2
and CCP3, however, was found in RF-negative patients
with a disease duration of ≤5 years. In this cohort
(n = 31), the sensitivity of CCP3 was 51.6% compared
to 38.7% for CCP2.
In sum, although the majority of studies comparing CCP2
and CCP3 detected no advantage of using CCP3 over CCP2, a
few studies showed a higher sensitivity of the anti-CCP3 pep-
tide assay compared to anti-CCP2 tests. Now, the CCP3 test
has been developed for analysis on an automated analyzer, the
BIO-FLASH instrument, and this assay may have different
properties as compared to ELISA-based assays. Therefore,
here, we analyzed the differences between anti-CCP2 and




Samples were obtained from 127 consecutive patients for
whom anti-CCP and IgM RF determination had been routine-
ly ordered for investigation of joint disease between
March 2013 and March 2014. Clinical data were retrospec-
tively collected between February and August 2015 by
reviewing the electronic medical records. Of the patients for
whom CCP was ordered, we assessed both the anti-CCP2
assay and the anti-CCP3 assay. On a total of 127 patients, 68
patients were diagnosed with RA according to the revised
1987 ACR diagnostic criteria, 59 were classified as non-RA.
The RA group was subdivided in patients with a disease du-
ration of less than 2 years (n = 26), between 2 and 5 years
(n = 18), and more than 5 years (n = 25). Furthermore, we
divided the RA group according to the RF status resulting in a
group of RF-positive patients (n = 47) and a group RF-
negative patients (n = 15). The non-RA group consists of
patients with osteoarthritis (n = 11), undifferentiated arthritis
(n = 10), crystal arthropathy (n = 4), psoriatic arthritis (n = 4),
and other diagnoses (n = 30). This last group consists of nine
patients with other inflammatory rheumatic diseases (SLE
n = 1, reactive arthritis n = 2, spondylartropathy n = 2, sys-
temic sclerosis n = 1, amyloidosis n = 1, andmixed connective
tissue disease n = 2) and 22 without clinical signs of an in-
flammatory rheumatic disease. Noteworthy, the group of un-
differentiated arthritis consists of patients with arthritis not
fulfilling the 1987 ACR criteria for RA up to 16 months of
follow-up.
Immunoassays
IgG anti-CCP2 antibodies and IgM RFwere determined using
the EliA™ technique (POhadia 250; Thermo Fisher
Scientific, Uppsala, Sweden). Anti-CCP3 antibodies were de-
termined using the Quanta Flash™ anti-CCP3 IgG kit (BIO-
FLASH Rapid Response Chemiluminscence Analyzer;
INOVA Diagnostics; San Diego, CA, USA). All assays were
analyzed at the central clinical chemistry laboratory of the
Leiden University Medical Centre.
Statistical analysis
In order to compare the diagnostic performance of the tests,
ROC analysis was performed. Furthermore, the areas under
the curve (AUC) of both tests were compared to investigate
whether one of the tests yielded significant advantages over
the other. We calculated alternative cut-off points by the
Youden’s index. Binary logistic regressions were used to in-
vestigate whether there is an advantage in diagnosing RA
when using both tests compared to using a single CCP2 or
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CCP3 test. All analyses were performed with Stata 14
software.
Results
Prevalence of anti-CCP2, anti-CCP3, and RF in different
disease cohorts
At the manufacturer’s cut-off point, 55/68 (80.9%) RA
patients were positive for anti-CCP2, 53/68 (78.0%) for
anti-CCP3 antibodies, and 45/68 (75.0%) for RF. In the
control group, 18/59 (30.5%) were positive for anti-
CCP2, 23/59 (39.0%) for anti-CCP3, and 19/57
(33.3%) for RF (Table 1). In the RF-negative RA group
(n = 15), 8/15 (53.3%) were positive for CCP2, and 9/15
(60.0%) were positive for CCP3. In the group of RA
patients with a disease duration less than 2 years, 20/26
(76.9%) were positive for anti-CCP2 as well as for anti-
CCP3. In the group of patients with disease duration
between 2 and 5 years, 13/18 (72.2%) were positive for
anti-CCP2 positive and 14/18 (77.8%) for anti-CCP3. In
patients with disease duration more than 5 years, 22/25
(88.0%) were CCP2 positive, and 20/25 (80.0%) were
CCP3 positive.
Sensitivity and specificity/likelihood ratios/predictive
values/area under the curve values obtained from ROC
analysis
In order to compare the diagnostic performance of the
tests, ROC analysis was performed for CCP2 and CCP3
tests (Fig. 1). Using the manufacturers cut-off value (for
CCP 2 < 7 U/ml and for CCP3 < 20 U/ml), the diagnostic
sensitivity for anti-CCP2 and anti-CCP3 was 80.9 and
79.4%, respectively, while the specificity was 69.5 and
61.0%, respectively. The AUC values were 0.79 (95%
CI: 0.71–0.87) for anti-CCP2 and 0.77 (95% CI: 0.69–
0.85) for anti-CCP3. The LR+/LR− were 2.65/0.28 for
anti-CCP2 and 2.04/0.34 for anti-CCP 3. In addition, the
positive predictive value for CCP2 and CCP3 were re-
spectively 75.3 (95% CI: 63.9–84.7) and 69.7% (95%
CI: 58.1–79.8), and the negative predictive value 75.9%
(95% CI: 62.4–86.5) for CCP2 and 70.6% (95% CI: 56.2–
82.5) for CCP3. When comparing the AUC of both ROC-
curves, no significant differences can be observed
(X2 = 0.41, p = 0.52). This result suggests there is no
advantage of using one over the other test. Furthermore,
Table 1 Prevalence of anti-
CCP2, anti-CCP3, and
rheumatoid factor in different
disease cohorts






RA 68 55 (80.9) 53 (78.0) 45 (75.0)
Disease duration
<2 years 26 20 (76.9) 20 (76.9) 18 (69.2)
≥2 and <5 years 18 13 (72.2) 14 (77.9) 10 (55.5)
≥5 years 25 22 (88.0) 20 (80.0) 20 (80.0)
RF status
RF negative 15 8 (53.3) 9 (60.0)
RF positive 47 41 (87.2) 38 (80.9)
Unknown 6 5 (83.3) 6 (100)
Non-RA 59 18 (30.5) 23 (39.0) 19 (33.3)
Osteoarthritis 11 1 (9.1) 4 (36.4) 1 (9.1)
Undifferentiated arthritis 10 5 (50.0) 7 (70.0) 5 (50.0)
Crystal arthropathy 4 1 (25.0) 1 (25.0) 1 (25.0)
Psoriatic arthritis 4 0 (0.0) 0 (0.0) 2 (50.0)
Others 30 11 (36.6) 10 (33.3) 9 (30.1)
Fig. 1 Comparative receiver operating characteristic (ROC) analysis for
CCP2 and CCP3. The ROC-curves for both tests were comparable as
shown by the area under the curve (AUC) values
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we calculated alternative cut-off points by the Youden’s
index. The optimal cut-off point for CCP2 was 10.5 U/ml
with a sensitivity of 75.0% and specificity of 80.0% and
5.6 U/ml for CCP3 reflecting a sensitivity of 87.0% and
specificity of 61.0%.
Binary logistic regressions
As there is apparently no advantage of using one over the
other test, it is worthwhile to explore whether a combination
of the two tests is advantageous for diagnosing RA. Therefore,
as a final analytical step, we ran binary logistic regressions
with RA and non-RA as our dependent variable, controlling
for gender and age. As can be observed in Table 2, model I
indicates that patients scoring positively on CCP2 tests have
8.71 higher odds of having RA. Controlling for gender and
age (both non-significant), 19% of the variation in outcome of
RA is explained. Furthermore, model II shows that patients
testing positive on CCP3 have 5.86 higher odds of having RA.
CCP3 explains 14% of variation. In model III, both positivity
of CCP2 and CCP3 are included. Both are significantly cor-
related with having RA, and the variation amounts to 22%. As
a result, it is worthwhile to investigate which combination of
CCP2 and CCP3 values yields higher probability of having
RA.







OR (SE) 95%CI OR (SE) 95%CI OR (SE) 95%CI
Constant 0.25 (.230) 0.04–1.49 0.20 (.182) 0.04–1.17 0.16 (.147)* 0.03–0.97
CCP2 positivity 8.71 (3.64)*** 3.84–19.77 5.56 (2.56)*** 2.25–13.72
CCP3 positivity 5.86 (2.37)*** 2.66–12.95 2.73 (1.27)* 1.10–6.78
Controls
Age 1.01 (.014) 0.99–1.04 1.02 (.013) 0.99–1.04 1.01 (.014) 0.99–1.04
Gender 0.60 (.278) 0.25–1.49 0.75 (.330) 0.32–1.78 0.66 (.311) 0.26–1.66
R2 .19 .14 .22
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Fig. 2 a Post-estimation of ROC-curve after logistic regression analysis,
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Fig. 3 Post-estimation of ROC-curve after logistic regression analysis,
CCP2, and CCP3
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The logistic regression models were followed up by ROC-
curves. As can be observed in Fig. 2a, b, the AUC values were
0.776 for anti-CCP2, and 0.739 for anti-CCP3. Combining
CCP2 and CCP3 yields an area under curve value of 0.800,
indicating an acceptable discriminating power of the model
(Fig. 3).
Finally, in order to investigate which combination of CCP2
and CCP3 values leads to a higher probability of having RA,
predicted probabilities of the combination of CCP2 and CCP3
values were calculated. In this analysis, we particularly focus
on the weakly positive values of CCP2 (≥7 and ≤10 U/ml). As
can be observed from Table 3, combining these weakly posi-
tive values of CCP2 with CCP3 can lead to a significant better
prediction of having RA, compared to using the values of
CCP2 alone.
Discussion
Anti-CCP antibodies are known to be an important serological
marker in the diagnosis of RA [2, 10, 21]. As a result, since
1998 several tests have been developed for a more accurate
identification of RA patients. Most recently, third generation
anti-CCP tests have been developed to increase the sensitivity
for the detection of patients with RA. However, the academic
literature comparing anti-CCP2 and anti-CCP3 assays pre-
sents conflicting evidence [7–18]. In this paper, we aimed to
advance current knowledge by investigating the diagnostic
performance of anti-CCP2 and anti-CCP3 assays separately
as well as in combination, in a setting of a routine patient
population.
Our analysis reveals no significant differences between the
AUC of both ROC-curves, indicating there is no advantage of
using one over the other test. However, the results clearly
indicate that a combination of both tests increases the likeli-
hood of diagnosing RA. Furthermore, although we observed a
trend of higher CCP3 in earlier and RF-negative RA, this
difference was not statistically significant. It is plausible this
finding is caused by the limited number of samples.
When we compare our results to previous studies, the spec-
ificity of both CCP tests is remarkably lower. This might be
attributed to the study design which was based on a routine
setting. Instead of comparing RA with a healthy non-RA
group, we included patients who were often already suspected
of having RA. However, we argue this population which is
particularly interesting for investigating whether CCP3 could
be of additive value for CCP2. Consequently, we tried to de-
fine a subgroup of patients—based on CCP2 values—where
CCP3 can be used as additive diagnostic value in diagnosing
RA. Our results clearly show that combining the weakly pos-
itive values of CCP2with CCP3 can lead to a significant better
prediction of having RA, compared to using CCP2 assay
alone. These findings suggest that a prediction model for hav-
ing RA based on CCP3 values, in populations of patients with
joint complaints and weakly positive CCP2, could be of addi-
tive value for clinical practice.
Conclusions
Our data demonstrate that anti-CCP2 and CCP3 show com-
parable performance characteristics in our patients’ popula-
tion. Although this conclusion should be taken with caution
because of the relatively small number of patients analyzed, it
is in line with previous studies. Of note, the specificity was
remarkably lower than reported in various studies which
should be considered when using the CCP test in a cohort with
a high number of related diseases. Positivity for both CCP2
and CCP3 resulted in the most specific identification of the
RA patients. Interestingly, however, this study shows that for
patients with joint complaints suspected of having RA and
with a weakly positive CCP 2 (≥7 and ≤16 U/ml), CCP3
testing could be of additive value for diagnosing RA.
Table 3 Combination of CCP2 and CCP3 values (U/ml), predicted probabilities of displaying RA (in percentages)
CCP3 values
CCP2 values PPV CCP2 57.4 61 63.7 66 69 70.5 74.4 76.2 191 339.6 501 736.2 972.4 2662.6
7 44.9 45.0 45.3 45.5 45.6 45.9 46.0 46.3 46.4 55.2 66.0 76.0 86.7 93.1 100
8 45.2 45.4 45.6 45.8 46.0 46.1 46.4 46.5 55.3 66.1 76.1 86.7 93.1 100
9 45.5 45.6 45.7 45.9 46.1 46.3 46.6 46.7 55.4 66.2 76.2 86.8 93.1 100
10 45.8 45.9 46.0 46.3 46.4 46.7 46.8 55.6 66.3 76.3 86.9 93.2 100
11 46.1 46.2 46.4 46.5 46.8 47.0 55.7 66.4 76.4 86.9 93.2 100
12 46.4 46.5 46.7 47.0 47.1 55.8 66.6 76.5 87.0 93.2 100
13 46.7 46.8 47.1 47.2 56.0 66.7 76.6 87.0 93.3 100
14 47.0 47.2 47.4 56.1 66.8 76.7 87.1 93.3 100
15 47.2 47.4 47.5 56.2 66.9 76.8 87.2 93.3 100
16 47.5 47.6 56.4 67.0 76.9 87.2 93.4 100
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